Cortexin vs Pinealon

Polypeptide bioregulator from bovine cortex; modulates neurotransmitter activity; activates GABA and dopamine systems; reduces excitotoxicity; stimulates neuronal repair

Cortexin is a polypeptide bioregulator derived from porcine cerebral cortex, used clinically in Russia and Eastern Europe as a neuroprotective and nootropic agent for stroke, traumatic brain injury, and chronic cerebrovascular disorders. It contains a complex mixture of tissue-specific neuropeptides, amino acids, and microelements proposed to support neuronal survival, reduce excitotoxic damage, and promote neurotrophic factor expression in injured brain tissue. Russian clinical trials have examined cortexin in acute ischemic stroke rehabilitation and other neurological conditions, with results suggesting potential benefit in functional recovery, though studies are predominantly published in Russian-language journals with limited methodological transparency by international standards. Cortexin is not FDA-approved; it is a licensed prescription drug in Russia and several post-Soviet states, where it has regulatory approval for neurological indications. Cortexin administration: in clinical settings where it is approved, cortexin is administered by intramuscular injection, typically as a 10 mg dose reconstituted in saline or procaine. Clinical courses in Russian practice involve daily injections over 10-day cycles, repeated 1–2 times per year for chronic neurological conditions. This administration pattern is common to several Russian polypeptide bioregulators, including cerebrolysin — another porcine-derived peptide mixture with a broader international clinical trial dataset — and cortagen, a cardiac-focus bioregulator from the same pharmacological class. Cortexin is the cerebral-cortex-specific member of this class; cortagen targets cardiovascular tissue, and thymalin targets thymic/immune tissue. Provider availability for cortexin outside Russia is limited compared to peptides with international regulatory approvals; it is occasionally carried by compounding pharmacies and specialized nootropic suppliers. The PeptideBase cognitive peptides directory lists verified providers who carry neuroprotective peptide compounds.

Glu-Asp-Arg tripeptide; penetrates blood-brain barrier; modulates gene expression in neurons; reduces oxidative stress in brain tissue

Pinealon is a synthetic tripeptide (Glu-Asp-Arg, EDR) classified as a Khavinson-class bioregulator peptide targeted at the pineal gland and central nervous system, investigated for neuroprotective and anti-aging properties in brain tissue. Like other short bioregulator peptides in the Khavinson series, pinealon is proposed to reach neuronal target cells via amino acid transporter mechanisms and modulate gene expression in aging neurons, with suggested effects on mitochondrial function and neuronal structural integrity. Published research on related Khavinson tripeptides has demonstrated restoration of neuronal spine density in in vitro models of Alzheimer's disease and modulation of epigenetic targets in aging neural tissue. Pinealon has not received FDA approval; evidence derives from Russian-origin preclinical studies and Khavinson-class literature, with no independent clinical trials published in Western indexed journals. Pinealon research interest centers on its role as a pineal gland bioregulator with neuroprotective and sleep-regulatory properties. As a pineal-derived peptide, pinealon is investigated for its potential to support melatonin pathway regulation, circadian rhythm maintenance, and age-related cognitive decline — areas where pineal gland function plays a central role. Research in aged animal models has examined pinealon-class peptides for effects on neuronal integrity, oxidative stress markers in brain tissue, and the preservation of sleep architecture with aging. The pineal gland produces melatonin and regulates circadian biology; as a targeted bioregulator for this tissue, pinealon represents an approach to age-associated disruptions in sleep quality and neuroendocrine signaling that is mechanistically distinct from melatonin supplementation itself. Pinealon as a peptide for sleep: Research interest in pinealon for sleep support derives from its classification as a pineal gland bioregulator. Unlike melatonin, which directly supplements a sleep hormone, pinealon is proposed to work upstream by supporting the regulatory function of the pineal gland itself — potentially offering a more targeted approach to age-related sleep disruption in a research context. This mechanism distinguishes pinealon from direct sedative or melatonin-based sleep interventions. Pinealon is a research compound; no clinical trials have established safety or efficacy for any indication including sleep support.